Last updated: September 2, 2026
Entacapone is a mature oral COMT inhibitor with limited active-ingredient patent risk in major markets. Commercial value is concentrated in generic tablets, fixed-dose combinations with levodopa/carbidopa, manufacturing-cost reduction, lactose-free formulations, and differentiated products that improve swallowing or adherence. The core formulation challenge is controlling dissolution for a poorly water-soluble, pH-dependent compound while maintaining tablet robustness and low-cost manufacture.
What formulations contain entacapone?
Entacapone is marketed primarily as a 200 mg immediate-release tablet and as the entacapone component in Stalevo fixed-dose tablets containing carbidopa and levodopa. Comtan is the reference standalone product; Stalevo is the principal combination product. FDA labeling states that entacapone is administered with each levodopa/carbidopa dose, with a maximum of eight 200 mg doses per day.[1,2]
| Product |
Active ingredients |
Main dosage form |
Commercial role |
| Comtan |
Entacapone 200 mg |
Immediate-release tablet |
Reference standalone product |
| Stalevo 50 |
Levodopa 50 mg, carbidopa 12.5 mg, entacapone 200 mg |
Immediate-release tablet |
Low levodopa strength |
| Stalevo 75 |
Levodopa 75 mg, carbidopa 18.75 mg, entacapone 200 mg |
Immediate-release tablet |
Intermediate strength |
| Stalevo 100 |
Levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg |
Immediate-release tablet |
Common maintenance strength |
| Stalevo 125 |
Levodopa 125 mg, carbidopa 31.25 mg, entacapone 200 mg |
Immediate-release tablet |
Intermediate strength |
| Stalevo 150 |
Levodopa 150 mg, carbidopa 37.5 mg, entacapone 200 mg |
Immediate-release tablet |
Higher levodopa strength |
| Stalevo 200 |
Levodopa 200 mg, carbidopa 50 mg, entacapone 200 mg |
Immediate-release tablet |
Highest levodopa strength |
The Stalevo formulation creates a larger development opportunity than standalone entacapone because the product combines three actives with different dose levels, physicochemical properties, color requirements and stability considerations.
Which excipients are used in Comtan and Stalevo?
The reference products use conventional tablet excipients. Public labeling identifies excipient classes including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate or another lubricant, hypromellose, sucrose, titanium dioxide and iron oxides, with formulation differences by product and strength.[1,2]
| Excipient or excipient class |
Primary function |
Entacapone-specific considerations |
| Lactose monohydrate |
Diluent |
Creates a cost-effective tablet base but limits use in lactose-avoidant markets and patient segments |
| Microcrystalline cellulose |
Diluent and compression aid |
Supports direct compression and tablet mechanical strength |
| Croscarmellose sodium |
Superdisintegrant |
Helps offset slow dissolution caused by low aqueous solubility |
| Povidone or related binder |
Granulation and binding |
Useful where wet granulation is needed to improve content uniformity |
| Magnesium stearate |
Lubricant |
Excessive concentration or mixing can slow wetting and dissolution |
| Hypromellose |
Film coating |
Supports color, identification and moisture protection |
| Sucrose |
Coating component |
Can increase coating complexity and moisture sensitivity |
| Titanium dioxide |
Opacifier |
Subject to jurisdiction-specific regulatory and customer restrictions |
| Iron oxides |
Colorant |
Supports product differentiation across multiple strengths |
| Colloidal silicon dioxide |
Glidant |
May improve powder flow and die filling in direct-compression processes |
The reference excipient system is commercially conservative. A generic manufacturer does not need to reproduce every excipient quantitatively, but it must demonstrate pharmaceutical equivalence, bioequivalence and acceptable product quality under the applicable ANDA pathway.[3]
What excipient strategy best addresses entacapone solubility?
Entacapone is practically insoluble in water and has pH-dependent solubility. The formulation objective is rapid and reproducible dissolution in the gastrointestinal environment rather than maximum drug loading alone. The most defensible strategy is a conventional immediate-release matrix with strong disintegration, controlled lubrication and tight particle-size specifications for the active ingredient.
Recommended formulation platform
A cost-efficient first-line platform would use:
- Microcrystalline cellulose as the principal compression aid.
- Croscarmellose sodium at a level sufficient to produce rapid tablet breakup.
- A limited amount of binder if granulation is required for flow or content uniformity.
- Magnesium stearate or sodium stearyl fumarate at the lowest validated concentration.
- A moisture-protective film coat where stability data justify it.
- A lactose-free diluent such as mannitol, anhydrous dibasic calcium phosphate or additional microcrystalline cellulose for differentiated products.
Direct compression may be attractive for a 200 mg single-active tablet. Wet granulation becomes more relevant for Stalevo because levodopa and carbidopa create a more complex blend with multiple dose ratios and a higher risk of segregation.
Critical quality attributes
The main formulation and manufacturing controls should cover:
- Assay and content uniformity of entacapone, levodopa and carbidopa.
- Dissolution across relevant pH conditions.
- Disintegration time.
- Tablet tensile strength and friability.
- Blend segregation during manufacture.
- Lubrication time and lubricant concentration.
- Residual moisture and water activity.
- Polymorphic or solid-state consistency of the active ingredient.
- Photostability and color stability.
- Impurity growth under accelerated and long-term storage.
A high-shear wet-granulation process may improve uniformity but can increase development cost and expose levodopa to moisture and oxidative stress. Direct compression reduces process steps but requires narrow control of powder flow, particle-size distribution and segregation.
What differentiated excipient opportunities exist for entacapone?
The strongest opportunities are incremental. Entacapone does not require a complex delivery platform for standard generic approval, but specific excipient strategies can support line extensions and private-label products.
Lactose-free entacapone tablets
A lactose-free tablet could target patients who avoid lactose and procurement systems that standardize on lactose-free oral solid dosage forms. Mannitol and microcrystalline cellulose are practical substitutes. The commercial advantage is greater for Stalevo-type combinations because patients take the product chronically and may use multiple Parkinson's medicines.
The substitute diluent must not materially alter dissolution, tablet hardness, moisture uptake or bioequivalence. Mannitol can improve mouthfeel but may increase tablet friability or require a different compression profile.
Low-cost direct-compression tablets
The reference formulation can be challenged on manufacturing economics rather than clinical differentiation. A direct-compression platform using microcrystalline cellulose, a superdisintegrant and a robust lubricant system could reduce granulation, drying and environmental-control costs.
The principal risk is poor blend uniformity, particularly when combining entacapone with lower-dose carbidopa in fixed-dose products. Process analytical technology, ordered mixing and engineered particle-size matching can reduce that risk.
Film-coated, swallow-optimized tablets
Parkinson's disease is associated with dysphagia in a substantial patient population. A smaller tablet, optimized shape, smoother coating and lower tablet mass may improve administration. A smaller standalone 200 mg tablet is constrained by active-ingredient loading, but excipient selection can reduce unnecessary coating and filler mass.
A swallow-optimized product is more likely to support a 505(b)(2) or line-extension strategy than a routine ANDA if it changes dosage form, administration method or labeling claims.
Orally disintegrating or dispersible products
An orally disintegrating entacapone product could address swallowing difficulty, but it would face formulation problems involving taste, dose mass and rapid dissolution. Entacapone's color and taste profile may require a carefully selected sweetener, flavor and taste-masking system.
An ODT containing the full 200 mg dose could be bulky. A dispersible tablet or multiparticulate system may be more practical, but both would require new performance and stability work. The opportunity is clinically relevant but commercially narrower than a conventional tablet.
Solubility-enhancing systems
Cyclodextrins, surfactants, amorphous solid dispersions and lipid-based systems could increase apparent solubility. These approaches may be unnecessary for a conventional immediate-release tablet and could create new risks involving stability, excipient exposure, scale-up and regulatory comparability.
A solubility-enhancing system is most defensible where it produces a measurable improvement in dissolution or reduces pharmacokinetic variability. It is less attractive if the reference product already meets rapid-release specifications without such technology.
When does entacapone lose exclusivity?
The principal U.S. market exclusivity for entacapone has expired. Comtan and Stalevo are mature products, and generic competition has been permitted through FDA abbreviated approval pathways. FDA Orange Book listings remain the operative source for current patents, exclusivity codes and reference-product information.[3]
| Exclusivity issue |
Current commercial assessment |
| Active-ingredient exclusivity |
Expired |
| New chemical entity exclusivity |
Expired |
| Standalone entacapone generic pathway |
Established |
| Fixed-dose levodopa/carbidopa/entacapone pathway |
More complex because of multiple active ingredients and strengths |
| Formulation patent risk |
Must be reviewed against current Orange Book listings and jurisdiction-specific records |
| Biosimilar risk |
Not applicable; entacapone is a small molecule |
| Paragraph IV risk |
Relevant only to any unexpired listed patent, not to the expired core compound rights |
The original compound and product patents are historical rather than current barriers in the U.S. Market entry analysis should focus on listed patents, regulatory exclusivity, ANDA status, manufacturing economics and supply reliability.
What is the Orange Book status of entacapone products?
The FDA Orange Book identifies reference-listed drugs, therapeutic equivalence information and patent or exclusivity data for approved products.[3] For a current ANDA strategy, the relevant checks are:
- Whether Comtan or Stalevo remains the reference-listed drug for the proposed strength.
- Whether any patent is listed against the specific strength or dosage form.
- Whether the patent is expired, delisted, or subject to a certification requirement.
- Whether the product has a therapeutic-equivalence rating that supports pharmacy substitution.
- Whether an applicant must make a Paragraph III, Paragraph IV, or other patent certification.
Because the standalone compound estate is mature, a Paragraph IV strategy would generally depend on a later-listed formulation, method-of-use or combination patent. A generic applicant should not assume that the absence of active ingredient patents eliminates all Orange Book issues.
What patent litigation and settlement risks affect entacapone?
The principal historical patent risk involved the branded Comtan and Stalevo products and their underlying compound, formulation and combination rights. The commercial significance of those rights has declined after expiration and generic entry.
For a current product launch, the relevant risks are narrower:
- A formulation patent directed to a specific dissolution profile or excipient system.
- A combination patent covering levodopa, carbidopa and entacapone.
- A method-of-use patent tied to dosing or motor-fluctuation treatment.
- A patent covering a new dosage form such as an ODT or dispersible tablet.
- Litigation over ANDA certification or product labeling.
A settlement agreement is commercially important only if it controls the first-filer launch date, volume restrictions, authorized-generic rights or royalty terms. No biosimilar interchangeability or biologic patent framework applies.
How does entacapone compare with competing Parkinson's drugs?
Entacapone competes with other adjunctive treatments for wearing-off in Parkinson's disease, including opicapone and tolcapone. The comparison is driven by dosing frequency, safety monitoring, generic availability and total treatment cost.
| Product |
Mechanism |
Typical dosing profile |
Commercial position |
| Entacapone |
Peripheral COMT inhibition |
Taken with each levodopa dose |
Generic, low-cost, higher pill burden |
| Opicapone |
Longer-acting COMT inhibition |
Once daily |
Branded or limited-generic opportunity, lower dosing frequency |
| Tolcapone |
COMT inhibition with greater liver-safety monitoring |
Multiple daily dosing |
Smaller commercial role because of hepatotoxicity concerns |
| Rasagiline or selegiline |
MAO-B inhibition |
Once or twice daily depending on product |
Mechanistically different adjunctive alternatives |
| Dopamine agonists |
Dopamine-receptor stimulation |
Product-specific |
Different adverse-effect and adherence profile |
Entacapone's commercial weakness is frequent dosing. Its advantage is established use, broad formulation familiarity and lower potential acquisition cost. A formulation that materially improves administration without creating a new regulatory burden would have the clearest commercial rationale.
What generic launch opportunities exist for entacapone?
The opportunity is strongest in five segments:
- Low-cost standalone 200 mg tablets.
- Complete generic coverage of all Stalevo strengths.
- Lactose-free and titanium-dioxide-free versions for institutional buyers.
- Contract-manufactured products for regional Parkinson's portfolios.
- Supply-secure dual-source products for markets with intermittent branded availability.
A manufacturer should prioritize a common platform across strengths, with color and imprint changes used for identification. For Stalevo, the manufacturing strategy should emphasize segregation control, uniformity and synchronized dissolution across all three active ingredients.
What geographic markets offer the best opportunity?
The U.S. is attractive for established generic substitution but has intense price competition. European markets have broader reference-product and generic procurement structures, with national differences in reimbursement and substitution. Emerging markets may offer better unit margins but can impose local registration, bioequivalence and manufacturing requirements.
Geographic protection for entacapone is unlikely to create a meaningful barrier around the expired core compound. Commercial differentiation will instead depend on:
- Local approval status.
- Reliable API sourcing.
- GMP-compliant manufacturing.
- Stability data for the target climatic zone.
- Packaging that limits moisture and light exposure.
- Government or hospital tender access.
- Availability of the full Stalevo strength range.
Key Takeaways
- Entacapone is a mature small-molecule generic opportunity with no biosimilar risk.
- The leading product platform is an immediate-release tablet containing 200 mg entacapone.
- Croscarmellose sodium, microcrystalline cellulose and controlled lubrication are central to dissolution and manufacturability.
- Lactose-free, low-cost direct-compression and swallow-optimized tablets offer the clearest excipient-led opportunities.
- Stalevo-type fixed-dose combinations are more technically difficult but provide broader portfolio value.
- Current patent analysis should rely on FDA Orange Book records and product-specific certifications rather than expired compound rights.
- The main commercial constraint is frequent dosing, not API exclusivity.
- Manufacturing barriers center on blend uniformity, levodopa stability, dissolution control and reliable supply.
FAQs About Entacapone Excipient and Patent Strategy
Can entacapone tablets be manufactured without lactose?
Yes. Mannitol, microcrystalline cellulose, dibasic calcium phosphate and other suitable diluents can replace lactose, subject to dissolution, stability, bioequivalence and manufacturability validation.
Is entacapone suitable for an orally disintegrating tablet?
Technically yes, but the 200 mg dose, taste, tablet size and dissolution profile create development challenges. A dispersible or swallow-optimized film-coated tablet may be more commercially practical.
Does entacapone have biosimilar competition?
No. Entacapone is a chemically synthesized small molecule. Competition proceeds through generic drug pathways rather than biosimilar applications.
What is the most important manufacturing risk for Stalevo generics?
The primary risk is content uniformity and segregation across levodopa, carbidopa and entacapone, especially when the formulation uses direct compression and contains low-dose carbidopa.
Can an excipient change create a new entacapone patent position?
Potentially. A novel excipient system may support a formulation patent if it produces a non-obvious and reproducible technical result, such as improved dissolution, stability, bioavailability or administration. Patentability does not eliminate the need to address Orange Book listing and generic regulatory requirements.
References
-
DailyMed. (n.d.). Comtan: Entacapone tablet, film coated, prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
DailyMed. (n.d.). Stalevo: Carbidopa, levodopa and entacapone tablet, film coated, prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. https://www.fda.gov/
-
European Medicines Agency. (n.d.). Stalevo: EPAR product information. https://www.ema.europa.eu/
